Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis

Peter P. Stanich; Dareen Elgindi; Elena Stoffel; Erika Koeppe; Ajay Bansal; Rachel Stetson; Debra L. Collins; Dana Farengo Clark; Eve Karloski; Beth Dudley; Randall E. Brand; Michael J. Hall; Yana Chertock; Brian A. Sullivan; Charles Muller; Alice Hinton; Bryson W. Katona; Sonia S. Kupfer

doi:10.14309/ajg.0000000000001996

Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis

Peter P. Stanich^*, Dareen Elgindi, Elena Stoffel, Erika Koeppe, Ajay Bansal, Rachel Stetson, Debra L. Collins, Dana Farengo Clark, Eve Karloski, Beth Dudley, Randall E. Brand, Michael J. Hall, Yana Chertock, Brian A. Sullivan, Charles Muller, Alice Hinton, Bryson W. Katona, Sonia S. Kupfer

^*Corresponding author for this work

Medicine, Gastroenterology Division

Research output: Contribution to journal › Article › peer-review

Abstract

INTRODUCTION:Germline variants in CDH1 are associated with elevated risks of diffuse gastric cancer and lobular breast cancer. It is uncertain whether there is an increased risk of colorectal neoplasia.METHODS:This was a retrospective analysis of colonoscopy outcomes in patients with germline CDH1 pathogenic/likely pathogenic variants.RESULTS:Eighty-five patients were included with a mean age of 46.9 years. Initial colonoscopy found adenomatous polyps in 30 patients (35.3%), including advanced adenomas in 9 (10.6%). No colorectal cancers were identified on index or subsequent colonoscopies (when available).DISCUSSION:CDH1 carriers have colorectal neoplasia identified at similar rates as in the general population. Despite potential difficulties after gastrectomy, colorectal cancer screening remains important in this population.

Original language	English (US)
Pages (from-to)	1877-1879
Number of pages	3
Journal	American Journal of Gastroenterology
Volume	117
Issue number	11
DOIs	https://doi.org/10.14309/ajg.0000000000001996
State	Published - Nov 1 2022

ASJC Scopus subject areas

Hepatology
Gastroenterology

UN SDGs

This output contributes to the following UN Sustainable Development Goals (SDGs)

Access to Document

10.14309/ajg.0000000000001996

Cite this

Stanich, P. P., Elgindi, D., Stoffel, E., Koeppe, E., Bansal, A., Stetson, R., Collins, D. L., Clark, D. F., Karloski, E., Dudley, B., Brand, R. E., Hall, M. J., Chertock, Y., Sullivan, B. A., Muller, C., Hinton, A., Katona, B. W., & Kupfer, S. S. (2022). Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis. American Journal of Gastroenterology, 117(11), 1877-1879. https://doi.org/10.14309/ajg.0000000000001996

@article{3a17edb4ccd54cb6a88f72f70715aa84,

title = "Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis",

abstract = "INTRODUCTION:Germline variants in CDH1 are associated with elevated risks of diffuse gastric cancer and lobular breast cancer. It is uncertain whether there is an increased risk of colorectal neoplasia.METHODS:This was a retrospective analysis of colonoscopy outcomes in patients with germline CDH1 pathogenic/likely pathogenic variants.RESULTS:Eighty-five patients were included with a mean age of 46.9 years. Initial colonoscopy found adenomatous polyps in 30 patients (35.3%), including advanced adenomas in 9 (10.6%). No colorectal cancers were identified on index or subsequent colonoscopies (when available).DISCUSSION:CDH1 carriers have colorectal neoplasia identified at similar rates as in the general population. Despite potential difficulties after gastrectomy, colorectal cancer screening remains important in this population.",

author = "Stanich, {Peter P.} and Dareen Elgindi and Elena Stoffel and Erika Koeppe and Ajay Bansal and Rachel Stetson and Collins, {Debra L.} and Clark, {Dana Farengo} and Eve Karloski and Beth Dudley and Brand, {Randall E.} and Hall, {Michael J.} and Yana Chertock and Sullivan, {Brian A.} and Charles Muller and Alice Hinton and Katona, {Bryson W.} and Kupfer, {Sonia S.}",

note = "Funding Information: Potential competing interests: P.P.S. receives research support from Emtora Biosciences, Janssen Pharmaceuticals, Pfizer, and the PTEN Research Foundation. B.A.S. receives support from Exact Sciences. B.W.K. receives research support from Epigenomics, Freenome, Guardant Health, Immunovia, and Janssen Pharmaceuticals and has consulted for Exact Sciences. S.S.K. receives research support from Immunovia and Invitae. No other authors have any potential conflicts to disclose. Funding Information: Financial support: This study was supported by the Ohio State University Center for Clinical and Translational Science grant (National Center for Advancing Translational Sciences, Grant UL1TR002733). B.A.S. is supported by the AGA Research Foundation{\textquoteright}s AGA Research Scholar Award—AGA2021-13-03. A.B. is supported by the NIH/NCI Cancer Center Support Grant P30 CA168524 to the University of Kansas Cancer Center. Publisher Copyright: {\textcopyright} 2021 American Heart Association, Inc.",

year = "2022",

month = nov,

day = "1",

doi = "10.14309/ajg.0000000000001996",

language = "English (US)",

volume = "117",

pages = "1877--1879",

journal = "American Journal of Gastroenterology",

issn = "0002-9270",

publisher = "Nature Publishing Group",

number = "11",

}

Stanich, PP, Elgindi, D, Stoffel, E, Koeppe, E, Bansal, A, Stetson, R, Collins, DL, Clark, DF, Karloski, E, Dudley, B, Brand, RE, Hall, MJ, Chertock, Y, Sullivan, BA, Muller, C, Hinton, A, Katona, BW & Kupfer, SS 2022, 'Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis', American Journal of Gastroenterology, vol. 117, no. 11, pp. 1877-1879. https://doi.org/10.14309/ajg.0000000000001996

TY - JOUR

T1 - Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers

T2 - A Multicenter Analysis

AU - Stanich, Peter P.

AU - Elgindi, Dareen

AU - Stoffel, Elena

AU - Koeppe, Erika

AU - Bansal, Ajay

AU - Stetson, Rachel

AU - Collins, Debra L.

AU - Clark, Dana Farengo

AU - Karloski, Eve

AU - Dudley, Beth

AU - Brand, Randall E.

AU - Hall, Michael J.

AU - Chertock, Yana

AU - Sullivan, Brian A.

AU - Muller, Charles

AU - Hinton, Alice

AU - Katona, Bryson W.

AU - Kupfer, Sonia S.

N1 - Funding Information: Potential competing interests: P.P.S. receives research support from Emtora Biosciences, Janssen Pharmaceuticals, Pfizer, and the PTEN Research Foundation. B.A.S. receives support from Exact Sciences. B.W.K. receives research support from Epigenomics, Freenome, Guardant Health, Immunovia, and Janssen Pharmaceuticals and has consulted for Exact Sciences. S.S.K. receives research support from Immunovia and Invitae. No other authors have any potential conflicts to disclose. Funding Information: Financial support: This study was supported by the Ohio State University Center for Clinical and Translational Science grant (National Center for Advancing Translational Sciences, Grant UL1TR002733). B.A.S. is supported by the AGA Research Foundation’s AGA Research Scholar Award—AGA2021-13-03. A.B. is supported by the NIH/NCI Cancer Center Support Grant P30 CA168524 to the University of Kansas Cancer Center. Publisher Copyright: © 2021 American Heart Association, Inc.

PY - 2022/11/1

Y1 - 2022/11/1

N2 - INTRODUCTION:Germline variants in CDH1 are associated with elevated risks of diffuse gastric cancer and lobular breast cancer. It is uncertain whether there is an increased risk of colorectal neoplasia.METHODS:This was a retrospective analysis of colonoscopy outcomes in patients with germline CDH1 pathogenic/likely pathogenic variants.RESULTS:Eighty-five patients were included with a mean age of 46.9 years. Initial colonoscopy found adenomatous polyps in 30 patients (35.3%), including advanced adenomas in 9 (10.6%). No colorectal cancers were identified on index or subsequent colonoscopies (when available).DISCUSSION:CDH1 carriers have colorectal neoplasia identified at similar rates as in the general population. Despite potential difficulties after gastrectomy, colorectal cancer screening remains important in this population.

AB - INTRODUCTION:Germline variants in CDH1 are associated with elevated risks of diffuse gastric cancer and lobular breast cancer. It is uncertain whether there is an increased risk of colorectal neoplasia.METHODS:This was a retrospective analysis of colonoscopy outcomes in patients with germline CDH1 pathogenic/likely pathogenic variants.RESULTS:Eighty-five patients were included with a mean age of 46.9 years. Initial colonoscopy found adenomatous polyps in 30 patients (35.3%), including advanced adenomas in 9 (10.6%). No colorectal cancers were identified on index or subsequent colonoscopies (when available).DISCUSSION:CDH1 carriers have colorectal neoplasia identified at similar rates as in the general population. Despite potential difficulties after gastrectomy, colorectal cancer screening remains important in this population.

UR - http://www.scopus.com/inward/record.url?scp=85141890333&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85141890333&partnerID=8YFLogxK

U2 - 10.14309/ajg.0000000000001996

DO - 10.14309/ajg.0000000000001996

M3 - Article

C2 - 36087100

AN - SCOPUS:85141890333

SN - 0002-9270

VL - 117

SP - 1877

EP - 1879

JO - American Journal of Gastroenterology

JF - American Journal of Gastroenterology

IS - 11

ER -

Colorectal Neoplasia in CDH1 Pathogenic Variant Carriers: A Multicenter Analysis

Abstract

ASJC Scopus subject areas

UN SDGs

Access to Document

Other files and links

Fingerprint

Cite this